The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19
Open accessAbstract
•Initiation of IVIG as adjuvant treatment for COVID-19 pneumonia within 48 h of admission to the ICU can reduce the use of mechanical ventilation.•Initiation of IVIG as adjuvant treatment for COVID-19 pneumonia within 48 h of admission to the ICU can reduce hospital length of stay and length of stay in ICU.•Initiation of IVIG as adjuvant treatment for COVID-19 pneumonia within 48 h of admission to the ICU can reduce 28-day mortality of patients with severe COVID-19 pneumonia. We read with interest the recent review by Han et al.1Han Q Lin Q Jin S et al.Coronavirus 2019-nCoV: A brief perspective from the front line.J Infect. 2020; (pii: S0163-4453(20)30087-6.[Epub ahead of print])https://doi.org/10.1016/j.jinf.2020.02.010Abstract Full Text Full Text PDF Scopus (201) Google Scholar that addressed the nature of the virus and its clinical characteristics to response to the COVID-19 outbreak. At present, there is no vaccine or specific drugs for the human coronavirus. The most effective measures to COVID-19 are still early detection and quarantine of new sources of infection, and early diagnosis and supportive treatments for comfirmed patients. As of March 18, 2020, China had a total of 81,151 confirmed cases of COVID-19, including those in health care workers. Italy, Japan, South Korea, the United States and other countries also reported new coronavirus cases, and the total global case load outside of China was 115,682 confirmed cases. The mortality rate of critically ill patients with the COVID-19 pneumonia is as high as 61.5%.2Yang Xiaobo Yu Yuan Xu Jiqian et al.Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered,retrospective, observational study.Lancet Respir Med. 2020; (Published OnlineFebruary 21, 2020)https://doi.org/10.1016/S2213-2600(20)30079-5Abstract Full Text Full Text PDF Scopus (6897) Google Scholar Intravenous immunoglobulin(IVIG) has been clinically used as an adjunctive drug in the treatment of severe pneumonia caused by influenza,3Ivan F.N Hung et al.Hyperimmune IV Immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection.Chest. 2013; 144: 464-473Abstract Full Text Full Text PDF PubMed Scopus (250) Google Scholar but there is controversy about its therapeutic effect on COVID-19 pneumonia, despite inclusion in the Trial Version 7 of National Health Commission & State Administration of Traditional Chinese Medicine stating that it can be considered for use in severe and critically ill patients. For this reason, this study retrospectively observed the relationship between the prognosis of patients with severe and critical COVID-19 pneumonia and the adjuvant therapy of IVIG and explored whether IVIG could improve the clinical symptoms, laboratory examination and prognosis of these patients. In this retrospective study, we reviewed 58 cases of severe or critical illness due to COVID-19 diagnosed in the intensive care unit of Wuhan Third Hospital from January to February 2020. The study was approved by the hospital's ethics committee and exempted from written informed consent. Inclusion criteria: All patients were diagnosed with COVID-19 and confirmed by real-time RT-PCR. Exclusion criteria: Patients with incomplete data. Severe criteria: Meet one of the following 1. Shortness of breath. RR ≥ 30 times/min 2. At rest, oxygen saturation ≤93%; 3. Arterial blood oxygen partial pressure/oxygen absorption concentration ≤300 mmHg. High altitude (>1000 m) areas should be calibrated according to the following formula: PaO2/FiO2 × [barometric pressure (mmHg)/760] 4. Pulmonary imaging showed obvious lesion progression ≥50% within 24-48 hours. Critical criteria: Meet one of the following: 1. Respiratory failure, requiring mechanical ventilation; 2. Shock; 3. Complications of other organ failure require ICU care. Primary outcome: 28-day mortality. Secondary outcomes: 14-day mortality, hospital length of stay, length of stay in the ICU, and use of mechanical ventilation. Grouping: >48 h group and ≤48 h group were divided according to the use of intravenous immunoglobulin within 48 h after admission. Our treatment plan was as follows: all patients received oxygen therapy and Abidor antiviral treatment and were initially administered the antibiotic moxifloxacin, according to the patient's clinical symptoms and signs and laboratory results, which were used to determine whether to adjust the antibiotics. In addition, according to the patient's condition, they were subjected to low molecular heparin anticoagulation, and when the absolute lymphocyte count fell to <0.5 × 109/L, they received intravenous immunoglobulin at 20 g/day and correction for hypoalbuminemia. If the absolute number of lymphocytes was still low five days later, we used Thymosin to boost immune function. Patients in critical condition received intravenous administration of small doses of glucocorticoids (1–
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
SARS: systematic review of treatment effects
Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217
Cited by
Piechotta, V., Chai, K. L., Valk, S. J., Doree, C., Monsef, I., Wood, E. M., Lamikanra, A., Kimber, C., McQuilten, Z., So-Osman, C., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013600.pub2 · Cited by 367
Pharmaco-Immunomodulatory Therapy in COVID-19
Rizk, J. G., Kalantar-Zadeh, K., Mehra, M. R., Lavie, C. J., Rizk, Y., & Forthal, D. N. (2020) · Drugs · doi:10.1007/s40265-020-01367-z · Cited by 288
Metadata
- Authors
- Xie, Y., Cao, S., Dong, H., Li, Q., Chen, E., Zhang, W., Yang, L., Fu, S., & Wang, R.
- Venue
- Journal of Infection
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 81
- Issue
- 2
- Pages
- 318-356
- ISSN
- 0163-4453 (ISSN-L)
- OpenAlex
- W3015728312
- Cited by
- 252
- References
- 2
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.